The short version of peptide analog fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-11 and is reviewed periodically as new material appears.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
In 1545, Charles Estienne was the first writer to identify the clitoris in a work based on dissection, but he concluded that it had a urinary function. Following this study, Realdo Colombo (also known as Renaldus Columbus), a lecturer in surgery at the University of Padua, Italy, published a book called De re anatomica in 1559, in which he describes the "seat of woman's delight". In his role as researcher, Colombo concluded, "Since no one has discerned these projections and their workings, if it is permissible to give names to things discovered by me, it should be called the love or sweetness of Venus.", about the mythological Venus, goddess of erotic love. Colombo's claim was disputed by his successor at Padua, Gabriele Falloppio (discoverer of the fallopian tube), who claimed that he was the first to discover the clitoris. In 1561, Falloppio stated, "Modern anatomists have entirely neglected it ... and do not say a word about it ... and if others have spoken of it, know that they have taken it from me or my students". This caused an upset in the European medical community, and, having read Colombo's and Falloppio's detailed descriptions of the clitoris, Vesalius stated, "It is unreasonable to blame others for incompetence on the basis of some sport of nature you have observed in some women and you can hardly ascribe this new and useless part, as if it were an organ, to healthy women".
== Further reading == "Becker Muscular Dystrophy (for Parents)." Edited by Mena T. Scavina, KidsHealth, The Nemours Foundation, Mar. 2018, kidshealth.org/en/parents/becker-md.html. Gaudio, Daniela del; Yang, Yaping; Boggs, Barbara A.; Schmitt, Eric S.; Lee, Jennifer A.; Sahoo, Trilochan; Pham, Hoang T.; Wiszniewska, Joanna; Craig Chinault, A.; Beaudet, Arthur L.; Eng, Christine M. (September 2008). "Molecular diagnosis of Duchenne/Becker muscular dystrophy: enhanced detection of dystrophin gene rearrangements by oligonucleotide array-comparative genomic hybridization". Human Mutation. 29 (9): 1100–1107. doi:10.1002/humu.20841. PMID 18752307. S2CID 21437006. Li, Xihua; Zhao, Lei; Zhou, Shuizhen; Hu, Chaoping; Shi, Yiyun; Shi, Wei; Li, Hui; Liu, Fang; Wu, Bingbing; Wang, Yi (2015). "A comprehensive database of Duchenne and Becker muscular dystrophy patients (0–18 years old) in East China". Orphanet Journal of Rare Diseases. 10 (1): 5. doi:10.1186/s13023-014-0220-7. PMC 4323212. PMID 25612904.
A day after his father's death, the National Assembly received clear instructions to dismiss Natchaba and elect Gnassingbé in his place, which would legalize his succession, which took place on 6 February 2005. Gnassingbé's election was unanimously approved by the deputies (98% of them were members of the ruling party) who were present in the National Assembly at the time; the opposition was not represented in the National Assembly due to its boycott of the 2002 parliamentary election. The members of Gnassingbé's then-party, the Rally of the Togolese People (RPT), did not want to challenge the army's choice. The parliament also eliminated a constitutional requirement that elections be held within 60 days of the president's death, enabling the younger Gnassingbé to rule until the expiration of his father's term in 2008. Under pressure from others in the region, and particularly Nigeria, later that month 2005, Gnassingbé announced that new elections would be held within 60 days, but said that he would remain in office in the meantime. However, on 21 February, the National Assembly reversed some of the constitutional changes that it had made so as to allow Gnassingbé to assume power, although it did not instruct him to resign. This was construed as a way of pressuring him to stand down with dignity. To change the constitution during a period of transition was itself an unconstitutional act, but this did not deter Gnassingbé's allies.
Sources: en.wikipedia.org
=== Comparison to other staple foods === The following table shows the nutrient content of raw plantain and other major staple foods in a raw form on a dry weight basis to account for their different water contents.
The Jardin des Vestiges (Occitan: Jardin dels Vesticis) is a garden containing the archaeological remains of the ancient port of Marseille, France. The site is located in the 1st arrondissement, behind the shopping arcade in the Centre Bourse. Classified as a French historical monument, it was excavated archaeologically in 1967 and officially opened on 17 October 2009. The site was part of the ancient Greek city of Massalia. It includes parts of the ancient port and city walls, with remains of three square towers and a gateway dating back to the second or third century BC.
== Relation to humans == Arapaima is exploited in many ways by local human populations. Its tongue is thought to have medicinal qualities in South America. It is dried and combined with guarana bark, which is grated and mixed into water. Doses are given to kill intestinal worms. The bony tongue is used to scrape cylinders of dried guarana, an ingredient in some beverages, and the bony scales are used as nail files. Arapaima produce boneless steaks and are considered a delicacy. In the Amazon region, locals often salt and dry the meat, rolling it into a cigar-style package that is then tied and can be stored without rotting, which is important in a region with little refrigeration. Arapaima are referred to as the "cod of the Amazon", and can be prepared in the same way as traditional salted cod. Designers have begun using the skin of the arapaima as leather to make jackets, shoes, and handbags, and to cover furniture. In July 2009, villagers around Kenyir Lake in Terengganu, Malaysia, reported sighting A. gigas. The "Kenyir monster", or "dragon fish" as the locals call it, was claimed to be responsible for the mysterious drowning of two men on 17 June. In August 2018, India Times reported that arapaima has been spotted in the Chalakudy River, following floods in Kerala; their presence in India is attributed to illegal importation for fish farming. The arapaima is depicted on both the flag and the seal of the Department of Ucayali, Peru.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.